CN201612748U - Biological pasted hot compress bag for dissolving stasis - Google Patents
Biological pasted hot compress bag for dissolving stasis Download PDFInfo
- Publication number
- CN201612748U CN201612748U CN201029151010XU CN201029151010U CN201612748U CN 201612748 U CN201612748 U CN 201612748U CN 201029151010X U CN201029151010X U CN 201029151010XU CN 201029151010 U CN201029151010 U CN 201029151010U CN 201612748 U CN201612748 U CN 201612748U
- Authority
- CN
- China
- Prior art keywords
- hirudin
- bag
- medical
- biological
- hot compress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000007625 Hirudins Human genes 0.000 claims abstract description 48
- 108010007267 Hirudins Proteins 0.000 claims abstract description 48
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 48
- 229940006607 hirudin Drugs 0.000 claims abstract description 48
- 239000000853 adhesive Substances 0.000 claims abstract description 40
- 230000001070 adhesive effect Effects 0.000 claims abstract description 34
- 239000004744 fabric Substances 0.000 claims abstract description 27
- 239000011248 coating agent Substances 0.000 claims abstract description 23
- 238000000576 coating method Methods 0.000 claims abstract description 23
- 238000007789 sealing Methods 0.000 claims abstract description 8
- 239000003364 biologic glue Substances 0.000 claims description 24
- 239000011505 plaster Substances 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 239000005030 aluminium foil Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 238000007920 subcutaneous administration Methods 0.000 abstract description 7
- 206010030113 Oedema Diseases 0.000 abstract description 2
- 206010047115 Vasculitis Diseases 0.000 abstract description 2
- 238000010241 blood sampling Methods 0.000 abstract description 2
- 208000001297 phlebitis Diseases 0.000 abstract description 2
- 239000002390 adhesive tape Substances 0.000 abstract 3
- 206010046996 Varicose vein Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000012856 packing Methods 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 description 12
- 229940127219 anticoagulant drug Drugs 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000237903 Hirudo Species 0.000 description 6
- 229910000831 Steel Inorganic materials 0.000 description 6
- 239000010959 steel Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 4
- 229960004408 lepirudin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000002429 anti-coagulating effect Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000429 cutaneous necrosis Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Surgical Instruments (AREA)
Abstract
The utility model relates to a biological pasted hot compress bag for dissolving stasis, which adopts the structure that a medical PVC woundplast adhesive tape (1) is arranged on the inner chamber of a sealing packing bag (6); a hirudin coating PVC medical cloth (2) is pasted on the front side of the woundplast adhesive tape; the hirudin coating PVC medical cloth is covered with non-setting adhesive protective plasters (3) and (4); and a hot compress bag (5) is pasted on the back side of the medical PVC woundplast adhesive tape (1). The hirudin coating PVC medical cloth (2) in the biological pasted hot compress bag adopts 1 to 5 mg hirudin containing about 7000 D molecular weight. The biological pasted hot compress bag for dissolving stasis provided by the utility model adopts the combined application of the hirudin and the hot compress bag, has obvious effect by compared with the effect played by applying a hot towel, and can really achieves the effect of eliminating extravasated blood safely, quickly and conveniently. Therefore, the biological pasted hot compress bag for dissolving stasis is worthy of popularization and use for varicosity, vasculitis, phlebitis and subcutaneous edema pain, and particularly on the aspect of treatment of the patient which easily generate subcutaneous extravasated blood after veinal blood sampling and infusion.
Description
Technical field
This utility model belongs to technical field of medical instruments, relates to the medical bio adhesive type stasis-eliminating hot compressing bag that contains the medical cloth of hirudin coating PVC.
Background technology
Be easy to generate subcutaneous extvavasated blood clinical vein blood sampling, transfusion back and physical property traumatic injury, gouge patient, cause local subcutaneous tissue and swelling pain occurs, influence limb function, severe patient can cause cutaneous necrosis, increase the patient suffering, and cause easily conflicting of nursing staff and patient.Need 2-4 week just can disappear generally speaking.Common way is with hot towel hot compress.The shortcoming of this way: 1, the variations in temperature of hot compress method such as hot towel is wayward.2, the temperature leak of hot towel comparatively fast can not keep uniform temperature for a long time.3, simple physiotherapy effect is undesirable.4, the hot compress time is not enough.Other way is a moisten compress therapy, is meant with the gauze dip in liquid medicine to apply a kind of method that disease is treated in the affected part.This method has effects such as suppressing to ooze out, to restrain antipruritic, reducing swelling and alleviating pain, control infection, promotion skin healing.For example the soak gauze that Adlerika is soaked spreads on the affected part, or the doctor gives the patient with the Adlerika and the gauze that prepare, enjoins gauze foldingly, spreads on the affected part after soaking with Adlerika.This way needs the doctor to make detailed description and interpretation on the one hand, and the patient carries and use equal inconvenience on the other hand; The used Adlerika of what is more important, gauze, utensil etc. can not guarantee to operate under the environmental condition of cleaning, cause bacteria attack easily, cause the infection in affected part, have increased the weight of patient's misery.
Hirudin is a kind of active substance of separating from the Hirudo salivary gland, has the effect that stops blood coagulation, and its mechanism is to cause the thrombin inactivation by the conjugated group of thrombin substrate in the occlude blood.The single chain polypeptide that hirudin is made up of 65 aminoacid, because trematodiasis kind difference, it is also different to contain the aminoacid number, majority contains 65 aminoacid, also there are some to contain 64 to 69 aminoacid, wherein the content of glutamine and N is higher, and relative molecular mass is 7000D, and isoelectric point, IP p I is 3.8.3 disulfide bond are arranged, and disulfide bond plays an important role for the stability of molecular configuration, is the key that keeps high anticoagulating active.At present, 7 kinds of isomers have been isolated.Hirudin is the most effective known natural anticoagulant, can effective anti-blood clotting, multiple thrombus disease such as phlebothrombosis, disseminated inravascular coagulation, brain blood coagulation, thrombophlebitis and crown arterial thrombus all there are prevention and therapeutic effect, particularly the thromboembolism again that reaches behind the surgical operation after dark bolt is treated are had important prevention and therapeutic effect.Therefore, hirudin will become the antithrombotic medicine of new anticoagulation.In at first finding the extract of Hirudo, Haycraft in 1884 contains anticoagulative substance, the pure product of isolating this anticoagulative substance of nineteen fifty-seven Markwardt success from Hirudo, and called after hirudin.Extract natural hirudin, because the restriction of raw material finite sum extracting method yields poorly it, the cost height has limited its clinical practice.
Foreign medical science blood transfusion and 1993 the 16th volumes of blood fascicle the 6th phase record Chinese Academy of Medical Sciences Blood Research Institute, Guo Juan summary Wang Hebi examines and revises " progress of lepirudin 023 ludon " Haycraft and found in the Hementaria officianalis extract anticoagulant substances is arranged in 1884.At the end of the fifties, Markwardt isolates pure product first, called after hirudin (Hirudin), and know that it is the special inhibitor of thrombin, be a kind of ideal anticoagulant, antithrombotic preparation.Learn its structure and amino acid sequence the beginning of the eighties.Loaded down with trivial details because of the natural hirudin extraction step, and raise the Hirudo difficulty, the Hirudo source is deficient, is difficult to obtain the pure product of q.s, and research and clinical practice are restricted.In recent years, the development of technique for gene engineering has remedied this defective, utilize chemosynthesis, cDNA library, PCR method to obtain gene clone, express and obtain lepirudin 023 ludon, thereby pharmacology, pharmacodynamics and the toxicity etc. of hirudin have more in depth been studied, a large amount of zooperies and clinic trial have been accelerated hirudin and have been applied to clinical process.At present, our laboratory is carrying out the research of HV1 cloning and expression.
Along with the molecular biology develop rapidly, external at present existing tens companies develop lepirudin 023 ludon and the plain preparation of functional Hirudo, a large number of experiments show that recombinant products is similar to natural prodcuts, are effective anticoagulant and antithrombotic preparation.The clinical indication of lepirudin 023 ludon can be summarized as follows: 1) clinical laboratory's anticoagulant; 2) internal medicine anticoagulant; 3) adjuvant of thrombolytic drug; 4) anticoagulant of angioplasty; 5) anticoagulant etc. in the hemodialysis.On the experimentation basis, carrying out clinical bulge test (as subacute and chronic DIC) at present.
The utility model content
In order to solve as above problem; the purpose of this utility model provides a kind of biological adhesive type stasis-eliminating hot compressing bag; it is by sealing bags (6) inner chamber medical PVC adhesive bandage adhesive plaster (1) to be set; post the medical cloth of hirudin coating PVC (2) in the front of adhesive bandage adhesive plaster; on the medical cloth of hirudin coating PVC, be coated with self-adhesive protection stick (3), (4), paste hot compress bag (5) at the back side of medical PVC adhesive bandage adhesive plaster (1) and constitute.
Biological adhesive type stasis-eliminating hot compressing bag described in the utility model is characterized in that the described medical cloth of hirudin coating PVC (2) is the 1-5mg hirudin that contains the about 7000D of molecular weight.
Biological adhesive type stasis-eliminating hot compressing bag described in the utility model, wherein the medical cloth of hirudin coating PVC (2) is medical adhesive-bonded fabric.
Biological adhesive type stasis-eliminating hot compressing bag described in the utility model, wherein sealing bags (6) is aluminium foil bag, medical plastic bag, the soft bag of composite membrane, hot co-extruded film soft bag or polrvinyl chloride bag.
Biological adhesive type stasis-eliminating hot compressing bag described in the utility model sticks hot compress bag at the medical band-aid adhesive plaster back side, helps the hirudin fast skin and absorbs, and hot compress promotes that also subcutaneous hemorrhage disappears fast in addition.Its benefit is:
1, hirudin has good blood stasis dispelling, blood coagulation resisting function.
2, hirudin can see through skin and directly affact the congestion place, performance hirudin anticoagulant blood maximum efficiency.
3, heat to local skin by hot compress bag, make subcutaneous extvavasated blood to dissipate fast.
4, hot compress bag has characteristics such as temperature constant, variations in temperature is very little, the hot compress time is long.
5, the use in conjunction of hirudin and hot compress bag can really accomplish to remove safely, fast, effectively, easily the effect of congestion than the remarkable enhancing of effect of the hot towel of simple application.
Hot compress bag described in the utility model has commercially available, its hot compress bag principle:
(1) the hot compress bag liberated heat is to have utilized the oxidized liberated heat of ferrum.
(2) carbon dust mainly acts on and is and ferrum and sodium chloride formation galvanic element, and ferrum is made negative pole, and carbon dust is done anodal.
(3) reaction equation in the entire reaction course is as follows:
2Fe-2e-＝＝2Fe
2+
O
2+2H
2O+4e-＝＝4OH-
Fe
2++2OH-＝＝Fe(OH)
2
4Fe(OH)
2+2H
2O+O
2＝＝4Fe(OH)
3
2Fe(OH)
3＝＝Fe
2O
3+3H
2O
Be actually the principle of in humid air, getting rusty according to ferrum.Utilize the strong adsorptivity of Linesless charcoal, in the open structure of Linesless charcoal, contain steam, along with the cooling of Linesless charcoal, steam is liquefied as water droplet, outflow contacts with iron powder with air, the generation hydrated ferric oxide. that under the catalytic action of sodium chloride, reacts comparatively rapidly, and emit heat.The sack material of hot compress bag is very special, and sack is to adopt the micro-porous permeable film production.In use, remove outer bag, allow the ventilated membrane sack be exposed in the air, react according to top chemical equation the inside that airborne oxygen enters by ventilated membrane, emits heat.
This utility model has carried out general stability study to biological adhesive type stasis-eliminating hot compressing bag, accelerated test: under integral packaging, sample is placed in the constant temperature, constant humidity incubator of 35 ℃ of relative humiditys 75%, temperature, observe and take out sample after 3 months, measure physical behavior indexs such as its adhesive force: (randomly drawing sample detects by 2005 editions appendix II of Chinese Pharmacopoeia and XII E)
| Inspection item | Standard code | Assay |
| [character]: | Outward appearance is white or little yellow, and the cream face should be bright and clean, thickness is even, color and luster is consistent, does not have to take off cream, lose glutinous phenomenon.The surface should be smooth, and clean, nothing is leaked the cream phenomenon.The length of adherent layer should be consistent with backing layer with width. | Outward appearance is a white, and the cream face is bright and clean, thickness is even, color and luster is consistent, does not have and takes off cream, the glutinous phenomenon of mistake.Surfacing, clean, nothing is leaked the cream phenomenon.The length of adherent layer is consistent with backing layer with width. |
| [adhesive force]: | The above steel ball of 13# 15 degree angles | The above steel ball of 16# 15 degree angles |
| [plastic property]: | Get test sample, put in 37 ℃, the climatic chamber of relative humidity 64% 30 minutes, take out, with clip test sample is fixed on the smooth steel plate, the inclination angle of steel plate and horizontal plane is 60 °, places 24 hours, and the cream face should not have the trickling phenomenon. | Get test sample, put in 37 ℃, the climatic chamber of relative humidity 64% 30 minutes, take out, with clip test sample is fixed on the smooth steel plate, the inclination angle of steel plate and horizontal plane is 60 °, places 24 hours, and the cream face does not have the trickling phenomenon. |
Biological adhesive type stasis-eliminating hot compressing bag of the present utility model, the hirudin of employing can see through skin and directly affact the congestion place, and can not produce stimulation and not pollute skin skin, and is without any side effects.
Result of the test of the present utility model shows: biological adhesive type stasis-eliminating hot compressing bag, reaction can obviously ease the pain.Wherein do not have pain or the mild pain rate is 93.33mg, and 2～5 grades of pain rates of matched group reach 82.14mg.Biological adhesive type stasis-eliminating hot compressing bag can be alleviated subcutaneous swelling and ache, so biological adhesive type stasis-eliminating hot compressing bag is being worth of widely use aspect the treatment of varicosis, vasculitis, phlebitis and subcutaneous dropsy pain patients.
Description of drawings
Fig. 1 is the structural representation of biological adhesive type stasis-eliminating hot compressing bag.Wherein 1 is medical PVC adhesive bandage adhesive plaster; 2 is the medical cloth of hirudin coating PVC; 3 is self-adhesive protection stick (right side); 4 is self-adhesive protection stick (left side); 5 is hot compress bag; 6 is sealing bags.
The specific embodiment
Below by the specific embodiment, foregoing of the present utility model is described in further detail, embodiment only is indicative, means that never it limits scope of the present utility model by any way.But do not breaking away under the above-mentioned technological thought situation of this utility model, the various replacements of making according to ordinary skill knowledge and habitual means or the modification of change include in scope of the present utility model.
Embodiment 1
Below in conjunction with accompanying drawing, describe the embodiment 1 of the biological adhesive type stasis-eliminating hot compressing of this utility model bag in detail.Fig. 1 is the front view of the biological adhesive type stasis-eliminating hot compressing of this utility model bag.As shown in Figure 1; the biological adhesive type stasis-eliminating hot compressing of this utility model bag; be medical PVC adhesive bandage adhesive plaster (1) to be set by sealing bags (6) inner chamber; post the medical cloth of hirudin coating PVC (2) in the front of adhesive bandage adhesive plaster; on the medical cloth of hirudin coating PVC, be coated with self-adhesive protection stick (3), (4), paste hot compress bag (5) at the back side of medical PVC adhesive bandage adhesive plaster (1) and constitute.The medical cloth of hirudin coating PVC (2) wherein contains the 2mg hirudin.
Preparation method is:
(1) under the working condition of 100,000 grades of cleanings, the 1mg hirudin is applied on the medical cloth of PVC, make the medical cloth of hirudin coating PVC, standby after checking content of dispersion and bacterial content qualified.
(2) the medical cloth of making of hirudin coating PVC is affixed on the medical band-aid adhesive plaster, covers adherent layer, as required cutting;
(3) hot compress bag is affixed on the medical band-aid adhesive plaster back side;
(4) pack-the medical plastic bag (should under the condition of local 100,000 grades of cleanings, finish), promptly get biological adhesive type stasis-eliminating hot compressing bag.
Embodiment 2
Below in conjunction with accompanying drawing, describe the embodiment 1 of the biological adhesive type stasis-eliminating hot compressing of this utility model bag in detail.Fig. 1 is the front view of the biological adhesive type stasis-eliminating hot compressing of this utility model bag.As shown in Figure 1; the biological adhesive type stasis-eliminating hot compressing of this utility model bag; be medical PVC adhesive bandage adhesive plaster (1) to be set by sealing bags (6) inner chamber; post the medical cloth of hirudin coating PVC (2) in the front of adhesive bandage adhesive plaster; on the medical cloth of hirudin coating PVC, be coated with self-adhesive protection stick (3), (4), paste hot compress bag (5) at the back side of medical PVC adhesive bandage adhesive plaster (1) and constitute.The medical cloth of hirudin coating PVC (2) wherein contains the 5mg hirudin.
Preparation method is:
(1) under the working condition of 100,000 grades of cleanings, the 5mg hirudin is applied on the medical cloth of PVC, make the medical cloth of hirudin coating PVC, standby after checking content of dispersion and bacterial content qualified.
(2) the medical cloth of making of hirudin coating PVC is affixed on the medical band-aid adhesive plaster, covers adherent layer, as required cutting;
(3) hot compress bag is affixed on the medical band-aid adhesive plaster back side;
(4) pack-the soft bag of composite membrane (should under the condition of local 100,000 grades of cleanings, finish), promptly get biological adhesive type stasis-eliminating hot compressing bag.
Claims (4)
1. biological adhesive type stasis-eliminating hot compressing bag; it is characterized in that it is by sealing bags (6) inner chamber medical PVC adhesive bandage adhesive plaster (1) to be set; post the medical cloth of hirudin coating PVC (2) in the front of adhesive bandage adhesive plaster; on the medical cloth of hirudin coating PVC, be coated with self-adhesive protection stick (3), (4), paste hot compress bag (5) at the back side of medical PVC adhesive bandage adhesive plaster (1) and constitute.
2. biological adhesive type stasis-eliminating hot compressing bag according to claim 1 is characterized in that the described medical cloth of hirudin coating PVC (2) is the hirudin of 1-5mg.
3. biological adhesive type stasis-eliminating hot compressing bag according to claim 1, wherein the medical cloth of hirudin coating PVC (2) is medical adhesive-bonded fabric.
4. biological adhesive type stasis-eliminating hot compressing bag according to claim 1, wherein sealing bags (6) is aluminium foil bag, medical plastic bag, the soft bag of composite membrane, hot co-extruded film soft bag or polrvinyl chloride bag.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201029151010XU CN201612748U (en) | 2010-02-08 | 2010-02-08 | Biological pasted hot compress bag for dissolving stasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201029151010XU CN201612748U (en) | 2010-02-08 | 2010-02-08 | Biological pasted hot compress bag for dissolving stasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201612748U true CN201612748U (en) | 2010-10-27 |
Family
ID=42999120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201029151010XU Expired - Fee Related CN201612748U (en) | 2010-02-08 | 2010-02-08 | Biological pasted hot compress bag for dissolving stasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201612748U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105617370A (en) * | 2016-01-28 | 2016-06-01 | 广州市当志强医药科技有限公司 | Hirudin blood stasis-removing paste and preparation method thereof |
| CN109223298A (en) * | 2018-08-10 | 2019-01-18 | 青岛沃普艾斯日用品有限公司 | A kind of pressure-sensitive Self-heating phytomicroorganism sunburn treatment hot compress paste and its manufacturing method |
-
2010
- 2010-02-08 CN CN201029151010XU patent/CN201612748U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105617370A (en) * | 2016-01-28 | 2016-06-01 | 广州市当志强医药科技有限公司 | Hirudin blood stasis-removing paste and preparation method thereof |
| CN109223298A (en) * | 2018-08-10 | 2019-01-18 | 青岛沃普艾斯日用品有限公司 | A kind of pressure-sensitive Self-heating phytomicroorganism sunburn treatment hot compress paste and its manufacturing method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mumcuoglu | Recommendations for the use of leeches in reconstructive plastic surgery | |
| US20120296266A1 (en) | Systems and Methods For Promoting Wound Healing | |
| Wei | The application of moist dressing in treating burn wound | |
| RU2015104803A (en) | PROLONGED ALLOCATION OF ACTIVE SUBSTANCES | |
| CN106581736A (en) | Medical adhesive prepared by adopting skin mucus of giant salamander as raw material and preparation method | |
| CN104857552A (en) | Hemostasis patch and preparation method thereof | |
| CN201612748U (en) | Biological pasted hot compress bag for dissolving stasis | |
| Ono | A study on the alterations in skin viscoelasticity before and after an intradermal administration of growth factor | |
| CN102908652A (en) | Composite hemostatic material mainly used for emergency aid | |
| CN109836533A (en) | A kind of liquid adhesive bandage and its preparation process | |
| CN208435924U (en) | A kind of antibacterial negative-pressure sealed drainage dressing suit | |
| CN101785765A (en) | Disposable hirudin stasis-eliminating hot compressing patch and applications thereof | |
| CN202207239U (en) | Novel wound plaster | |
| CN105520844B (en) | Bletilla polysaccharide and Paeonol composition product and its application | |
| CN201082179Y (en) | Pressurization hemostasis concave plaster | |
| CN115970044B (en) | Double-layer chitosan hemostatic sponge and preparation method thereof | |
| CN206391081U (en) | A kind of cotton balls adhesive bandage | |
| CN108815182B (en) | Sterilized compound magnesium sulfate wet-dressing composition as well as preparation method and application thereof | |
| CN202086668U (en) | War wound analgesic paste | |
| CN2640447Y (en) | Healing promotion wound plaster | |
| SE0301546L (en) | Biocompatible polymer | |
| CN2735989Y (en) | Combination injection sterilizing apparatus | |
| CN209827628U (en) | Aloe paste | |
| CN102160861A (en) | Infusion medicament analgesic patch | |
| CN212940621U (en) | Transdermal plaster |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20160817 Granted publication date: 20101027 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20170607 Granted publication date: 20101027 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170711 Address after: Fifth Street 300450 Tianjin City Development Zone, Taihua Road No. 12 TEDA SME development center room 3024 Patentee after: Tianjin hundred new biotechnology research and Development Co., Ltd. Address before: 300384 Tianjin Huayuan Industrial Park Torch Hotel 501 Patentee before: Tianjin Baili Kangtai Biological Technology Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101027 Termination date: 20190208 |